Resistance to the HIV Protease Inhibitor Amprenavir In Vitro and in Clinical Studies
- 1 October 2000
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 20 (4) , 267-285
- https://doi.org/10.2165/00044011-200020040-00008
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experienceAIDS, 1999
- Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.Journal of Antimicrobial Chemotherapy, 1998
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- AmprenavirDrugs, 1998
- In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agentsAntiviral Research, 1996
- 141W94Drugs of the Future, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988